Skip to content

Study · Non-randomized trial · n = 60 · 2019

4 results

[Evaluation of the efficacy and safety of application of the drug cortexin in the complex rehabilitation of verticalization in patients with ischemic stroke in the acute period].

Mashin VV, Belova LA, Aizatullin IF, Pavlova VA, Slasten EV, Abramova VV, Belov DV

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2019Cited by 2 (Europe PMC)

PMID31626220 (opens in a new tab)DOI10.17116/jnevro201911909162 (opens in a new tab)PepBankPUB-31626220
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In acute ischemic stroke, cortexin plus basic therapy and early verticalization reduced neurological deficits most completely compared with basic therapy and early verticalization.

    In plain wordsIn acute ischemic stroke, adding cortexin to basic therapy and early verticalization reduced neurological deficits more completely.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    DecreaseNeurological deficits versus early verticalization
    Study

    n = 60

    Comparator
    Basic therapy with early verticalization
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    20 mg per day · intramuscular · 10 daysAs given in this study (human).

    Source sentences

    Summary
    The most complete regression of neurological deficits and manifestations of cardiac autonomic neuropathy during the acute period of ischemic stroke was observed in the group of patients treated with cortexin (20 mg per day for 10 days), along with basic therapy and early verticalization,
    5 context sentences
    Summary · context
    compared to the groups, which received basic therapy with early verticalization or basic therapy without verticalization.
    Summary · context
    The study included 90 patients with hemispheric ischemic stroke.
    Summary · context
    Patients of the first group (n=30) received cortexin in a dose of 20 mg per day intramuscularly for 10 days, along with basic therapy during early verticalization.
    Summary · context
    Patients of the second group (n=30) received basic therapy during early verticalization and patients of the third group (n=30) received only basic therapy without verticalization.
    Summary · context
    All studies were conducted before and 10-14 days after treatment.
  2. 02HumanNon-randomized trialEfficacy outcome

    In acute ischemic stroke, adding cortexin to basic therapy and early verticalization produced more complete regression of cardiac autonomic neuropathy.

    In plain wordsIn acute ischemic stroke, adding cortexin to basic therapy and early verticalization reduced cardiac autonomic neuropathy more completely.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    DecreaseCardiac autonomic neuropathy versus early verticalization
    Study

    n = 60

    Comparator
    Basic therapy with early verticalization
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    20 mg per day · intramuscular · 10 daysAs given in this study (human).

    Source sentences

    Summary
    The most complete regression of neurological deficits and manifestations of cardiac autonomic neuropathy during the acute period of ischemic stroke was observed in the group of patients treated with cortexin (20 mg per day for 10 days), along with basic therapy and early verticalization,
    5 context sentences
    Summary · context
    compared to the groups, which received basic therapy with early verticalization or basic therapy without verticalization.
    Summary · context
    The study included 90 patients with hemispheric ischemic stroke.
    Summary · context
    Patients of the first group (n=30) received cortexin in a dose of 20 mg per day intramuscularly for 10 days, along with basic therapy during early verticalization.
    Summary · context
    Patients of the second group (n=30) received basic therapy during early verticalization and patients of the third group (n=30) received only basic therapy without verticalization.
    Summary · context
    All studies were conducted before and 10-14 days after treatment.

Studies that did not test the peptide alone2

In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cortexin (cortical polypeptide complex).

  1. 03HumanNot a test of Cortexin (cortical polypeptide complex) aloneNon-randomized trialEfficacy outcome

    In acute ischemic stroke, cortexin plus basic therapy and early verticalization reduced neurological deficits more completely than basic therapy without verticalization.

    In plain wordsIn acute ischemic stroke, cortexin plus basic therapy and early verticalization reduced neurological deficits more completely than basic therapy without verticalization.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    DecreaseNeurological deficits versus basic therapy
    Study

    n = 60

    Comparator
    Basic therapy without verticalization
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The most complete regression of neurological deficits and manifestations of cardiac autonomic neuropathy during the acute period of ischemic stroke was observed in the group of patients treated with cortexin (20 mg per day for 10 days), along with basic therapy and early verticalization,
    5 context sentences
    Summary · context
    compared to the groups, which received basic therapy with early verticalization or basic therapy without verticalization.
    Summary · context
    The study included 90 patients with hemispheric ischemic stroke.
    Summary · context
    Patients of the first group (n=30) received cortexin in a dose of 20 mg per day intramuscularly for 10 days, along with basic therapy during early verticalization.
    Summary · context
    Patients of the second group (n=30) received basic therapy during early verticalization and patients of the third group (n=30) received only basic therapy without verticalization.
    Summary · context
    All studies were conducted before and 10-14 days after treatment.

    In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).

  2. 04HumanNot a test of Cortexin (cortical polypeptide complex) aloneNon-randomized trialEfficacy outcome

    In acute ischemic stroke, cortexin plus basic therapy and early verticalization reduced cardiac autonomic neuropathy more completely than basic therapy without verticalization.

    In plain wordsIn acute ischemic stroke, cortexin plus basic therapy and early verticalization reduced cardiac autonomic neuropathy more completely than basic therapy without verticalization.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    DecreaseCardiac autonomic neuropathy versus basic therapy
    Study

    n = 60

    Comparator
    Basic therapy without verticalization
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    The most complete regression of neurological deficits and manifestations of cardiac autonomic neuropathy during the acute period of ischemic stroke was observed in the group of patients treated with cortexin (20 mg per day for 10 days), along with basic therapy and early verticalization,
    5 context sentences
    Summary · context
    compared to the groups, which received basic therapy with early verticalization or basic therapy without verticalization.
    Summary · context
    The study included 90 patients with hemispheric ischemic stroke.
    Summary · context
    Patients of the first group (n=30) received cortexin in a dose of 20 mg per day intramuscularly for 10 days, along with basic therapy during early verticalization.
    Summary · context
    Patients of the second group (n=30) received basic therapy during early verticalization and patients of the third group (n=30) received only basic therapy without verticalization.
    Summary · context
    All studies were conducted before and 10-14 days after treatment.

    In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.